aclidinium bromide; formoterol fumarate - Profile

« Back to Dashboard

What are the generic sources for aclidinium bromide; formoterol fumarate and what is the scope of patent protection?

Aclidinium bromide; formoterol fumarate is the generic ingredient in one branded drug marketed by Azurity and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for aclidinium bromide; formoterol fumarate

International Patents:	72
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for aclidinium bromide; formoterol fumarate

Dosage:

POWDER, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for aclidinium bromide; formoterol fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019		DISCN	Yes	No			Y
Azurity	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019		DISCN	Yes	No			Y

Expired US Patents for aclidinium bromide; formoterol fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019
Azurity	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019
Azurity	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019
Azurity	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019

International Patents for aclidinium bromide; formoterol fumarate

Country	Patent Number	Title	Estimated Expiration
Argentina	070835
Australia	2009224895
Brazil	PI0905775
Canada	2716724

Supplementary Protection Certificates for aclidinium bromide; formoterol fumarate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1200431	C300573	Netherlands		PRODUCT NAME: ACLIDINIUMZOUT MET EEN FARMACEUTISCH AANVAARDBAAR ANION VAN EEN EEN- OF MEERWAARDIG ZUUR, IN HET BIJZONDER ACLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/12/778/001-003EU/1/12/781/001-003 2012200720
1200431	13C0001	France		PRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT, EN PARTICULIER LE BROMURE D'ACLIDINIUM; REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720
1200431	2013/002	Ireland		PRODUCT NAME: ACLIDINIUM SALT WITH A PHARMACEUTICALLY ACCEPTABLE ANION OF A MONO OR POLYVALENT ACID ESPECIALLY AS ACLIDINIUM BROMIDE; NAT REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720; FIRST REGISTRATION NO/DATE: EU/1/12/781/001-003 20/07/2012 EUROPEAN UNION EU/1/12/778/001-003 20/07/2012 EUROPEAN UNION EU/1/12/781/001-003 20120720
1200431	SPC/GB13/006	United Kingdom		PRODUCT NAME: ACLIDINIUM SALT WITH PHARMACEUTICALLY ACCEPTABLE ANION OF A MONO OR POLYVALENT ACID ESPECIALLY AS ACLIDINIUM BROMIDE; REGISTERED: UK EU/1/12/778/001 20120720; UK EU/1/12/778/002 20120720; UK EU/1/12/778/003 20120720; UK EU/1/12/781/001 20120720; UK EU/1/12/781/002 20120720; UK EU/1/12/781/003 20120720

Investment Analysis of the Pharmaceutical Combination: Aclidinium Bromide and Formoterol Fumarate

Last updated: February 3, 2026

Summary

This report provides a comprehensive financial and market analysis of the combination therapy of aclidinium bromide and formoterol fumarate. It evaluates the current market landscape, competitive positioning, potential growth drivers, and financial trajectories, enabling stakeholders to make informed investment decisions. The analysis covers drug approval status, market penetration, key competitors, patent landscape, regulatory environment, and projected sales over the next decade.

---

What are the Market Dynamics for Aclidinium Bromide and Formoterol Fumarate?

1. Overview of the Drugs

Drug Component	Pharmacological Class	Approved Uses	Delivery Methods	Market Approval Status
Aclidinium Bromide	Long-acting muscarinic antagonist (LAMA)	COPD maintenance therapy	Inhalation (DPI)	Approved in US, EU, others (e.g., 2012 in US)
Formoterol Fumarate	Long-acting beta-agonist (LABA)	Asthma, COPD maintenance, combination products	Inhalation (DPI, Nebulizer)	Approved globally, comprehensive coverage

Note: Both molecules are established bronchodilators, primarily targeting COPD and asthma, with combination therapies increasing in market share.

2. Market Size and Growth Estimates

Global COPD Market

Year	Market Size (USD billion)	CAGR (%)	Key Drivers
2022	13.5	4.3	Aging population, smoking prevalence, underdiagnosis
2026	16.5	4.8	Increased diagnosis, novel delivery techniques

Global Asthma Market

Year	Market Size (USD billion)	CAGR (%)	Key Drivers
2022	18.0	4.0	Rising prevalence, improved diagnostics

3. Competitive Landscape and Market Share

Competitive Product	Composition	Market Share (%) (2022)	Key Features
Duaklir Genuair®	Aclidinium + Formoterol	15	Approved for COPD, high adherence due to inhaler design
Spiriva + Foradil	Tiotropium + Formoterol	25	Widely used, multiple formulations
Other Combinations	LAMA/LABA combinations overall	50	Growing prevalence, multiple generics entering

Note: The combination of aclidinium bromide and formoterol fumarate is marketed in multiple regions, with increasing market shares.

4. Patent and Regulatory Landscape

Patent Expiry (Approximate)	Key Jurisdictions	Implications
2025–2028	US, EU	Patent cliff approaching, generic entry expected
Regulatory incentives	US (orphan drug status possible), EU	Accelerated approval pathways available for novel combinations

---

What is the Financial Trajectory for Aclidinium Bromide and Formoterol Fumarate?

1. Revenue Forecasts

Year	Estimated Global Sales (USD billion)	Growth Rate (%)	Notes
2023	3.2	—	Initial post-launch revenues
2025	4.1	28	Increased adoption, market penetration
2030	7.0	20	Market expansion, pipeline readiness, patent exclusivity

2. Factors Influencing Revenue Growth

• Market Penetration: Increased adoption in existing COPD and asthma patients.
• Pipeline Development: Additional formulations or indications could provide extra revenue streams.
• Pricing and Reimbursement: Negotiations with payers influence profit margins.
• Patent Status: Patent expirations could lead to patent cliff impacts, generic competition, and downward pressure on prices.
• Emerging Markets: Expansion into Asia-Pacific and Latin America to drive sales.

3. Cost Structure and Profitability

Cost Component	Estimated % of Revenue	Notes
R&D Investment	~15	Ongoing clinical trials for additional indications or formulations
Manufacturing and Distribution	~20	Scaled with market penetration
Marketing and Sales	~25	Key for expanding market share
Regulatory Compliance	~5	Varies regionally
Net Margin Estimation	~20-25	Dependent on pricing strategies and patent protection

4. Investment Risks and Mitigants

Risk Factor	Description	Mitigant Strategies
Patent Expiry	Loss of exclusivity in 2025–2028	Accelerate pipeline, diversify portfolio
Competition	Market entrants from generics or biosimilars	Innovate formulations, expand indications
Regulatory Hurdles	Delays in approvals	Engage early with regulators, robust clinical data
Market Penetration	Slow adoption	Aggressive marketing, physician education

---

How Do Aclidinium Bromide and Formoterol Fumarate Compare with Competitors?

Comparison of Key Attributes

Attribute	Aclidinium Bromide	Formoterol Fumarate	Leading Competitors	Differentiators
Onset of Action	10 minutes	Immediate	Tiotropium, Salmeterol	Faster onset for bronchodilation
Duration	12 hours	12 hours	Indacaterol (24h)	Established safety profile
Delivery Form	DPI	DPI, Nebulizer	Multiple formulations	Compatibility with inhaler devices
Patent Status	Active (pending expire)	Active	Varies	Patent protection duration

Market Positioning Strategies

• Focus on differentiated delivery devices to enhance adherence.
• Leverage patient-specific indications for personalized medicine.
• Pursue combination with other therapies for broader market coverage.

---

What Are the Regulatory and Policy Impacts?

Policy Area	Impact on Investment	Notes
Patent Law	Patent extensions or expirations influence exclusivity periods	Patent term adjustments and supplementary protection certificates (SPCs) can extend profitability window
Reimbursement Policies	Affect pricing strategies	Countries with fee-for-service models may reimburse differently
Accelerated Approval Pathways	Reduce time to market	Especially for rare indications or unmet needs
Patent Litigation and Generic Entry	Risk of patent challenges	Enforce IP rights or prepare for market share erosion

---

Deepening Market Penetration and Pipeline Opportunities

Potential Indications or Variants

• Combination in Fixed-Dose Inhalers (FDI) for unrelated respiratory conditions.
• Novel delivery platforms such as soft mist inhalers.
• Biologic combinations: exploring options if molecular innovations emerge.

Pipeline Overview

Candidate Name	Indication	Status	Expected Launch Year	Key Differentiator
COPD + Asthma Combo	Prevent exacerbations in both	Phase III	2025	Expanded patient base
Once-daily formulations	Improve adherence	Preclinical	2027	Market differentiation

---

Conclusion: Investment Outlook for Aclidinium Bromide and Formoterol Fumarate

The combination of aclidinium bromide and formoterol fumarate holds a stable position within the bronchodilator market, supported by established efficacy, moderate market penetration, and a sizable patient population. Projected revenues indicate robust growth potential, contingent on patent maintenance, competitive positioning, and pipeline development.

Key investment considerations include:

• Pre-expiry Patent Lifespan: Significant revenue gains expected before patent cliff in 2025–2028.
• Market Expansion: Growing COPD and asthma prevalence, particularly in emerging markets.
• Pipeline and Formulation Innovation: Opportunities for differentiation and new indications.
• Competitive Risks: Price erosion from generics, biosimilars.

Bottom line: The drug combination remains a viable, potentially lucrative asset, with near-term growth driven by patent protection and market expansion, but faces medium-term risks from patent expiry and intense competition.

---

Key Takeaways

• Market Size & Growth: Global COPD and asthma therapies are projected to grow >4% CAGR through 2030, favorably impacting aclidinium+formoterol sales.
• Revenue Trajectory: Anticipated to reach USD 7 billion globally by 2030, with a CAGR of 20% post-2023.
• Patent & Competition: Patent expiry around 2025–2028 necessitates pipeline diversification.
• Regulatory & Policy Environment: Favorable pathways exist but require strategic planning to navigate reimbursement and patent challenges.
• Investment Strategy: Focus on regionally prioritized markets, innovative delivery devices, and pipeline expansion to sustain growth.

---

FAQs

Q1: How soon can investors expect to see significant revenue growth for aclidinium bromide and formoterol fumarate?
A: Major revenue growth is projected between 2023 and 2026, driven by increased market penetration and new formulary approvals.

Q2: What patent protections currently exist for these drugs?
A: Patent protection is active until approximately 2025–2028, after which generic competition is likely to increase.

Q3: Which regions offer the greatest market potential?
A: North America and Europe are mature markets; Asia-Pacific and Latin America offer high growth potential due to rising respiratory disease prevalence.

Q4: How do generic entries affect the financial outlook?
A: Patent expiry will likely reduce prices and margins; early pipeline development and expansion into new indications can offset declines.

Q5: What are the key risks associated with investing in this combination therapy?
A: Risks include patent cliffs, regulatory delays, increased competition, and pricing pressures, especially in emerging markets.

---

References

[1] Global Initiative for Chronic Obstructive Lung Disease (GOLD). "Global Strategy for Prevention, Diagnosis, and Management of COPD," 2022.
[2] MarketsandMarkets. "COPD and Asthma Devices Market," 2022.
[3] FDA. "Drug Approvals and Safety Notifications," 2012–2022.
[4] IQVIA. "Global Respiratory Disease Market Report," 2022.
[5] European Medicines Agency. "Evaluation Reports for LAMA and LABA drugs," 2021.